My HPRA: Register

HPRA Drug Safety Newsletter Edition 82

Download: hpra-drug-safety-newsletter-edition-82.pdf 217 KB

 The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines: 

 

  • Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment

     

  • Gabapentin – respiratory depression without concomitant opioid use

     

  • Amoxicillin; co-amoxiclav – very rare reports of DRESS (drug reaction with eosinophilia and systemic symptoms)

     

  • Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter 

« Back